Additional file 1 of Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer

Additional file 1 Supplementary Table 1. ESRP1 and prostate cancer phenotype in ERG-negative (n = 4211) and ERG-positive (n = 3339) cancers. For statistical analysis contingency tables and the chi2-test were performed. Supplementary Table 2. ESRP2 and prostate cancer phenotype in ERG-negative (n = 4555) and ERG-positive (n = 3508) cancers. For statistical analysis contingency tables and the chi2-test were performed. Supplementary Figure 1. ESRP1 and common chromosomal deletions. For statistical analysis contingency tables and the chi2-test were performed. Supplementary Figure 2. Validation of ESRP1 and ESRP2 antibodies. ESRP1: Strong staining in ESRP1 overexpressing Hela cells (positive control) and no staining in HeLa wildtype cells (negative control). ESRP2: Strong staining in ESRP2 overexpressing Hela cells (positive control) and no staining in Hela wildtype cells (negative control).